|
|
RED Abemaciclib |
NICE TA563 Recommended, within its marketing authorisation, with an aromatse inhibitor, as an option for treating locally |
advanced or metastatic, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2) - negative |
breast cancer as first endocrine-based therapy in adults. (only recommended if the company provides it according to |
the commercial arrangement. Cancer Drugs Fund |
NICE TA579 Abemaciclib with fulvestrant - this guidance has been replaced by NICE TA725 [15th September 2021] |
|
NICE TA725 Abemaciclib with fulvestrant is recommended as an option for treating hormone receptor-positive, human |
epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer in adults who have had |
endocrine therapy only if: |
> exemestane plus everolimus is the most appropriate alternative to a cyclin‑dependent kinase 4 and 6 (CDK 4/6) |
inhibitor and |
> the company provides abemaciclib according to the commercial arrangement. |
NHS England Commissioned |
RED Abemaciclib [Verzenios] |
NICE TA810 Abemaciclib with endocrine therapy is recommended, within its marketing authorisation, as an option for |
adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer in adults whose |
disease is at high risk of recurrence, defined by the following clinical and pathological features: |
> at least 4 positive axillary lymph nodes, or |
> 1 to 3 positive axillary lymph nodes, and at least one of the following criteria: |
- grade 3 disease (defined as at least 8 points on the modified Bloom-Richardson grading system or |
equivalent), or |
- primary tumour size of at least 5cm. |
See full guidance NHS England Commissioned |
RED Acalabrutinib [Calquence®] |
NICE TA689 Recommended as an option, as monotherapy, for untreated chronic lymphocytic leukaemia (CLL) in adults, only if: |
> there is a 17p deletion or TP53 mutation, or |
> there is no 17p deletion or TP53 mutation, and fludarabine plus cyclophosphamide and rituximab, or |
bendamustine plus rituximab is unsuitable, and |
the company provides the drug according to the commercial arrangement. NHS England Commissioned |
RED Alectinib |
NICE TA536 Recommended as an option for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell |
cancer in adults. NHS England Commissioned |
|
RED Alpelisib [Piqray] plus fulvestrant |
NICE TA816 Recommended as an option for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally |
advanced or metastatic breast cancer in adults, only if: |
> their cancer has progressed after a CDK4/6 inhibitor plus ab aromatose inhibitor and |
> the company provides alpelisib according to the commercial arrangement |
This guidance updates and replaces TA652 on apelisib with fulvestrant [terminated appraisal] |
NHS England Commissioned |
RED Arsenic trioxide |
NICE TA526 Recommended, within its marketing authorisation, as an option for inducing remission and consolidation in |
acute promyelocytic leukaemia (characterised by the presence of the t[15;17] translocation or the PML/RAR-alpha |
gene) in adults with: |
> untreated, low-to-intermediate risk disease (defined as a white blood cell count of 10x10³ per microlitre or less), |
when given with all-trans-retinoic acid (ATRA) |
> relapsed or refractory disease, after a retinoid and chemotherapy NHS England Commissioned |
RED Asciminib [Scemblix] |
NICE TA813 Asciminib is recommended, within its marketing authorisation, as an option for treating chronic-phase Philadelphia |
chromosome-positive chronic myeloid leukaemia without a T315l mutation after 2 or more tyrosine kinase inhibitors in |
adults. It is recommended only if the company provides asciminib according to the commercial arrangement. |
NHS England Commissioned |
RED Atezolizumab |
NICE TA520 For treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy. |
Recommended as an option in in adults who have had chemotherapy (and targeted treatment if they have |
an EGFR- or ALK‑positive tumour), only if: |
> atezolizumab is stopped at 2 years of uninterrupted treatment or earlier if the disease progresses and |
> the company provides atezolizumab with the discount agreed in the patient access scheme. |
(NHS England Commissioned) |
NICE TA525 For treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy |
Recommended as an option in only if: |
> atezolizumab is stopped at 2 years of interrupted treatment or earlier if the disease progresses and |
> the company provides atezolizumab with discount agreed in the patient access scheme |
(NHS England Commissioned) |
NICE TA584 Atezolizumab plus bevacizumab, carboplatin and paclitaxel is recommended as an option for metastatic non- squamous on-small-cell lung cancer (NSCLC)in adults: |
> who have not had treatment for their metastatic NSCLC before and whose PD-L1 tumour proportion score is |
between 0% and 49% or |
> when targetted therapy for epidermal growth factor receptor (EGFR)-positive or anaplastic lymphoma kinase |
(ALK)-positive NSCLC has failed. |
It is recommended only if: |
> atezolizumab and bevacizumab are stopped at 2 years of uninterrupted treatment, or earlier if there is loss of |
clinical benefit (for atezolizumab) or if the disease progresses (for bevacizumab) and |
> if the company provides atezolizumab and bevacizumab according to the commercial arrangements. |
NICE TA638 Atezolizumab with carboplatin and etoposide is recommended as an option for untreated extensive-stage small-cell |
lung cancer in adults, only if: |
> they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and |
> the company provides atezolizumab according to thecommercial arrangement |
|
NICE TA639 Atezolizumab with nab-paclitaxel is recommended, within its marketing authorisation, for treating triple negative, |
unresectable, PD-L1-positive, locally advanced or metastatic breast cancer in adults whose tumours express PD-L1 at a |
level of 1% or more and who have not had previous chemotherapy for metastatic disease. It is recommended only if |
the company provides atezolizumab according to the commercial arrangement |
NICE TA666 Atezolizumab plus bevacizumab is recommended as an option for treating advanced or unresectable hepatocellular |
carcinoma [HCC] in adults who have not had previous systemic treatment, only if: |
> they have Child-Pugh grade liver impairment and an Eastern Cooperative Oncology Group [ECOG] performance |
status of 0 or 1 and |
> the company provides it according to the commercial arrangement (NHS England Commissioned) |
NICE TA705 Atezolizumab is recommended within its marketing authorisation, as an option for untreated metastatic non-small-cell |
lung cancer in adults if: |
> their tumours have PD-L1 expression on at least 50% of tumour cells or 10% of tumour-infiltrating immune cells |
> their tumours do not have epidermal growth factor receptor or anaplastic lymphoma kinase mutations and |
> the company provides atezolizumab according to the commercial arrangement. (NHS England Commissioned) |
NICE TA823 Atezolizumab is recommended for use within the Cancer Drugs Fund as an option for adjuvant treatment after |
complete tumour resection in adults with stage 2 to 3a non-small-cell lung cancer (NSCLC) whose: |
> tumours have the programmed cell death ligand‑1 (PD‑L1) biomarker expression on 50% or more of their tumour |
cells and |
> whose disease has not progressed after platinum-based adjuvant chemotherapy. |
It is recommended only if the company provides atezolizumab according to the managed access agreement. |
Cancer Drugs Fund |
RED Axicabtagene ciloleucel therapy |
NICE TA872 Recommended, within its marketing authorisation, as an option for treating relapsed or refractory diffuse large B-cell lymphoma or primary |
mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies. It is recommended only if the company provides |
axicabtagene ciloleucel according to the commercial arrangement. NHS England Commissioned |
This guidance updates and replaces NICE TA559 |
|
RED Axitinib |
NICE TA333 Recommended as an option for treating adults with advanced renal cell carcinoma after failure of treatment with a |
first line tyrosine kinase inhibitor or a cytokine, only if the compant provides axitinib with the discount agreed in the |
patient access scheme. |
RED Bortezomib |
NICE TA129 Recommended as an option for the treatment of progressive multiple myeloma in people who are at first relapse |
having received one prior therapy and who have undergone, or are unsuitable for, bone marrow transplant, under the |
circumstances listed in the guidance. |
NICE TA228 Bortezomib and thalidomide for the first-line treatment of multiple myeloma: |
1. Thalidomide in combination with an alkylating agent and a corticosteroid is recommendaed as an option for the first |
line treatment of multiple myeloma in people for whom high-dose chemotherapy with stem cell transplantation is |
considered inappropriate |
2. Bortezomib in combination with an alkylating agent and a cortiscosteroid is recommended as an option for the |
first-line treatment of multiple myeloma if: |
> a high dose chemotherapy with stem cell transplantation is considered inappropraite and |
> the person is unable to tolerate or has contraindications to thalidomide |
NICE TA311 Recommended as an option within its marketing authorisation, that is, in combination with dexamethasone, or with |
dexamethasone and thalidomide, for the induction treatment of adults with previously untreated multiple myeloma, |
who are eligible for high-dose chemotherapy with haematopoietic stem cell transplant. |
NICE TA370 Recommended, within its marketing authorisation, as an option for previously untreated mantle cell lymphoma in |
adults for whom haemotopoietic stem cell transplantation is unsuitable. |
RED Bosutinib (Bosulif) |
NICE TA401 Recommended as an option, within its marketing authorisation, for chronic accelerated and blast phase Philadelphia |
chromosome positive chronic myeloid leukaemia in adults, when: |
> they have previously had 1 or more tyrosine kinase inhibitor and |
> imatinib, nilotinib and dasatinib are not appropriate and |
> the company provides bosutinib with the discount agreed in the patient access scheme (as revised in 2016) |
RED Brentuximab vedotin (Adcetris®) |
NICE TA524 Recommended as an option for treating CD30- positive Hodgkin Lymphoma in adults with relapsed or refractory |
disease only as specified in NICE TA524 |
This guidance is a Cancer Drugs Fund reconsideration of NICE TA446 and replaces TA446 |
(NHS England Cancer Drugs Fund) |
NICE TA478 Recommended as an option for treating relapsed or refractory systemic anapplastic large cell lymphoma in adults |
(NHS England Commissioned) |
NICE TA577 Recommended as an option for treating CD30-positive cutaneous T-cell lymphoma (CTCL) after at least 1 systemic |
therapy in adults, only if: |
> they have mycosis fungoides stage IIB or over, primary cutaneous anaplastic large cell lymphoma |
or Sézary syndrome and |
> the company prvides brentuximab vedotin according to the commercial arrangement |
NICE TA641 Recommended within its marketing authorisation, with cyclophosphamide, doxorubicin and prednisolone, as an |
option for untreated systemic anaplastic large cell lymphoma in adults. (NHS England Commissioned) |
|
RED Brexucabtagene autoleucel (Tecartus) |
NICE TA893 Recommended for use within the Cancer Drugs Fund as an option for treating relapsed or refractory B‑cell acute |
lymphoblastic leukaemia in people 26 years and over. It is recommended only if the conditions in |
the managed access agreement for brexucabtagene autoleucel are followed. NHSE Cancer Drug Fund |
RED Brigatinib (Alunbrig) |
NICE TA571 Recommended, within its marketing authorisation, for treating anaplastic lymphoma kinase (ALK)-positive advanced |
non-small-cell lung cancer in adults who have already had crizotinib, It is recommended only if the company |
provides it according to the commercial arrangement. (NHS England Commissioned) |
NICE TA670 Recommended, within its marketing authorisation, for treating anaplastic lymphoma kinase [ALK]-positive advanced |
non-small-cell lung cancer that has not been previously treated with an ALK inhibitor in adults |
(NHS England Commissioned) |
RED Cabazitaxel |
NICE TA391 In combination with prednisone or prednisolone is recommended an option for treating metastatic hormone-relapsed |
prostate cancer in people whose disease has progressed during or after docetaxel chemotherapy. |
RED Cabozantinib |
NICE TA463 An option for treating advanced renal cell carcinoma in adults after vascular endothelial growth factor- targeted |
therapy. (NHS England Commissioned) |
NICE TA516 Recommended , within its marketing authorisation, as an option for treating progressive medullary thyroid cancer in |
adults with unresectable, locally advanced or metastatic disease. (NHS England Cancer Drugs Fund) |
NICE TA 849 Recommended as an option for treating advanced hepatocellular carcinoma in adults who have had sorafenib, only if: |
> they have Child–Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and |
> the company provides it according to the commercial arrangement. |
NICE TA849 updates and replaces NICE TA542 NHS England Commissioned |
|
RED Carboplatin injection 150mg/15mL, 450mg/45mL |
RED Carfilzomib powder For solution for infusion |
NICE TA657 Recommended as an option in combination with dexamethasone for treating multiple myeloma in adults only if: |
> they have had only 1 previous therapy, which did not include bortezomib and |
> the company provides carfilzomib with the discount agreed in the patient access scheme. |
NICE TA657 updates and replaces TA457 NHS England Commissioned |
|
NICE TA695 Recommended as an option with lenalidomide and dexamethasone for treating multiple myeloma in adults, only if: |
> they have had only 1 previous therapy, which included bortezomib, and |
> the company provides carfilzomib according to the commercial arrangement |
Partially updates NICE TA657 NHS England Commissioned |
RED Cemiplibab |
NICE TA592 updated and replaced by NICE TA802 |
NICE TA802 Recommended as an option for treating metastatic or locally advanced cutaneous squamous cell carcinoma |
in adults when curative surgery or curative radiotherapy is not suitable, only if: |
> it is stopped at 24 months, or earlier if their disease progresses, and |
> the company provides cemiplimab according to the commercial arrangement |
This guidance updates and replaces NICE TA592 |
RED Ceritinib |
NICE TA395 Recommended within its marketing authorisation, as an option for treating advanced anaplastic lymphoma |
kinase positive non-small-cell lung cancer in adults who have previously had crizotinib. The drug is recommended |
only if the company provides it with the discount agreed in the patient access scheme. |
NICE TA500 Recommended within its marketing authorisation, as an option for untreated anaplastic kinase (ALK)-positive |
advanced non-small-cell cancer in adults, only if the company provides it with the discount agreed in the patient |
access scheme. (NHS England Commissioned) |
RED Cetuximab infusion 5mg/mL |
NICE TA439 (updated Sept 2017) Cetuximab and panitumumab is recommended, as an option for previously untreated |
metastatic colorectal cancer |
NICE TA473 In combination with platinum based chemotherapy is recommended as an option for treating recurrent or metastatic |
squamous cell cancer of the head and neck in adults only. (NHS England Commissioned) |
RED Cisplatin injection 50mg |
RED Crizotininb capsules 200mg, 250mg |
NICE TA406 Recommended as an option, within its marketing authorisation, for untreated anaplastic lymphoma kinase-positive |
advanced non-small-cell cancer in adults. (NHS England Commissioned) |
NICE TA422 An option in previously treated anaplastic lymphoma kinase-positive advanced on-small-cell lung cancer in adults |
NICE TA529 Recommended for use within the Cancer Drugs Fund as an option for treating ROS1- positive advanced |
non-small-cell lung cancer in adults only if the conditions in the managed access agreement are followed. |
(NHS England Cancer Drugs Fund) |
RED Dabrafenib |
NICE TA321 Recommended as an option, within its marketing authorisation, for treating unrescectable or metastatic BRAF V600 |
mutation-positive melanoma [only if the company provides darafenib with the discount agreed in the patient access |
scheme. |
NICE TA544 Dabrafenib with trametinib is recommended, within its marketing authorisation, an option for the adjuvant treatment |
of resected stage III BRAF V600 mutation-positive melanoma in adults as per (NHS England Commissioned) |
NICE TA898 Dabrafenib plus trametinib is recommended as an option for treating BRAF V600 mutation-positive advanced |
non-small-cell cancer in adults, only if: |
> it is used as first-line treatment of advanced stage cancer, and |
> the company provides it according to the commercial arrangement. |
This guidance updates and replaces NICE TA564 |
RED Dacomitinib tablets 45mg (Vizimpro®) |
NICE TA595 Recommended, within its marketing authorisation, as an option for untreated locally advanced or metastatic |
epidermal growth factor receptor [EGFR] mutation-positive non-small-cell lung cancer in adults. It is recommended |
only if the company provides it according to the commercial arrangement. (NHS England Commissioned) |
RED Daratumumab |
NICE TA510 This guidance has been updated and replaced by NICE TA783 |
|
NICE TA573 This guidance has been updated and replaced by NICE TA897 |
|
NICE TA763 Daratumumab plus bortezomib, thalidomide and dexamethasone is recommended, within its marketing |
authorisation, as induction and consolidation treatment for untreated multiple myeloma in adults, when an |
autologous stem cell transplant is suitable. NHS England Commissioned |
NICE TA783 Daratumumab monotherapy is recommended as an option for treating relapsed and refractory multiple myeloma in |
adults who have had a proteasome inhibitor and an immunomodulator, and whose disease progressed on the last |
treatment, only if: |
> they have daratumumab after 3 treatments and |
> the company provides daratumumab according to the commercial arrangement |
Replaces NICE TA510 |
NICE TA897 Daratumumab with bortezomib and dexamethasone is recommended as an option for treating multiple myeloma in |
adults, only if they have had just 1 previous line of treatment and: |
> it included lenalidomide or |
> lenalidomide is unsuitable as a second-line treatments and |
> the company provides it according to the commercial arrangement. |
This guidance updates and replaces NICE TA573 NHS England Commissioned |
RED Dasatinib |
NICE TA425 Dasatininb is recommended as an option in treating only chronic- or accelerated-phase Philadelphia-chromosome- |
positive chronic myeloid leukaemia in adults. [Replaces NICE TA241] (NHS England Commissioned) |
NICE TA426. Dasatinib is recommended as an option for untreated chronic-phase Philadelphia- chromosome-positive |
chronic myeloid leukaemia in adults [Replaces NICE TA251} (NHS England Commissioned) |
RED Dacarbazine injection 1g |
RED Dinutuximab beta |
NICE TA538 Dinutuximab is recommended as an option for treatin g high-risk neuroblastoma in people aged 12 months and |
over whose disease has at least partially responded to induction chemotherapy, followed by myeloablative therapy |
and stem cell transplant (NHS England Commissioned) |
RED Docetaxel injection 20mg/0.5ml, 80mg/2ml (NICE indications only) |
|
RED Dostarilumab |
NICE TA779 Dostarilumab is recommended for use within the Cancer Drugs Fund as an option for treating advanced or recurrent |
endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had |
platinum-based chemotherapy. It is recommended only if the conditions in the managed access agreement are |
followed, Cancer Drugs Fund |
RED Encorafenib |
NICE TA562 Encorafenib with binimetinib is recommended, within its marketing authorisation, as an option for treating |
unresectable or metastatic BRAF V600 mutation-positive melanoma in adults. (NHS England Commissioned) |
NICE TA668 Encorafenib plus cetuximab is recommended, within its marketing authorisation, as an option for treating |
BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment. |
(NHS England Commissioned) |
RED Entrectinib [Rozlytek] |
NICE TA643 Recommended within its marketing authorisation, as an option for treating ROS1-positive advanced non-small-cell |
lung cancer in adults who have not had ROS1 inhibitors. (NHS England Commissioned) |
NICE TA644 Recommended for use within the Cancer Drugs Fund as an option for treating neurotropic tyrosine receptor kinase |
[NTRK] fusion-positive solid tumours in adults and children 12 years and older if; |
> the disease is locally advanced or metastatic or surgery could cause severe health problems and |
> they have not had and NTRK inhibitor before and |
> they have no satisfactory treatment options (Cancer Drugs Fund) |
RED Eribulin solution for injection 0.8mg/2ml, 1.32mg/3ml. |
NICE TA423 Eribulin is recommended as an option for treating locally advanced or metastatic breast cancer in adults who have |
had 2 or more courses of chemotherapy. (replaces NICE TA250) (NHS England Commissioned) |
RED Erlotinib tablets 25mg, 100mg, 150mg (NICE indication only) |
NICE TA374 Erlotinib is recommended as an option for treating locally advanced or metastatic non-small-cell lung cancer |
that has progressed after prior chemotherapy. (NHS England Commissioned) |
RED Everolimus 2.5mg, 5mg, 10mg tablets, |
NICE TA421 in combination with exemestane is recommended as an option for treating advanced breast cancer after |
endocrine therapy (NHS England Commissioned) |
NICE TA432 recommended as an option for treating advanced renal cell carcinoma that has progressed during or after treatment |
with vascular endothelial growth factor targeted therapy, only if the company provides it with the discount agreed in |
the patient access scheme. (NHS England Commissioned) |
NICE TA449 unresectable or metastatic neuroendocrine tumours (NETs) of pancreatic origin in adults with progressive disease. |
(NHS England Commissioned) |
|
RED Fedratinib [Inrebic] capsules 100mg |
NICE TA756 Recommended for use within the Cancer drugs Fund as an option for treating disease-related splenomegaly of |
primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocytopenia myelofibrosis |
in adults. It is recommended only if: |
> they have previously had ruxolitinib and |
> the conditions in the managed access agreement for fedratinib are followed. |
Cancer Drugs Fund |
RED Gilteritinib [Xospata] 40mg tablets |
NICE TA642 Recommended as an option for treating relapsed or refractory FLY3-mutation-positive acute myeloid leukaemia in |
adults only if the company provides gilteritinib according to the commercial arrangement. |
(NHS England Commissioned) |
RED Hydroxycarbamide capsules 500mg - unlicensed use for psoriasis in adults. Specialist initiation only. |
|
RED Gefitinib tablets 250mg |
RED Gemtuzumab oxogamicin |
NICE TA545 with daunorubicin and cytarabine is recommended as an option for untreated de novo CD33-positive acute myeloid |
leukaemia in people aged 15 years and over. (NHS England Commissioned) |
RED Ibrutinib capsules 140mg as an option for treating chronic lymphocytic leukaemia in adults who have had at least 1 |
prior therapy or, who have a 17p deletion or TP53 mutation, and in whom chemotherapy is unsuitable as per |
NICE TA429 (NHS England Commissioned) |
Ibrutinib NICE TA491 this has been updated and replaced by NICE TA795 [BLACK TRAFFIC LIGHT: |
|
RED Ibrutinib is recommended as an option for treating relapsed or refractory mantle cell lymphoma in adults only if they |
have had 1 previous line of therapy and the company provides ibrutinib with the agreed discount in the commercial |
access agreement with NHS England as in NICE TA502 (NHS England Commissioned) |
|
RED Ibrutinib with venetoclax is recommended, within its marketing authorisation, as an option for untreated chronic |
lymphocytic leukaemia (CLL) in adults. This is only if the companies provide both drugs according to the commercial |
arrangements. NICE TA891 NHS England Commissioned |
RED Idelalisib (Zydelig®) tablets 100mg, 150mg - as an option in NICE TA359 for treating chronic lymphocytic leukaemia |
|
RED Imatinib [Glivec] |
NICE TA326 Recommended as an option as adjuvant treatment for up to 3 years for adults who are at high risk of relapse |
after surgery for KIT (CD117)-positive gastrointestinal stromal tumours, as defined by the Miettinen 2006 crtieria |
(based on tumour size, location and mitotic rate). |
NICE TA425 This guidance replaces NICE TA421 (NHS England Commissioned) |
|
NICE TA426 Recommended as an option for untreated, chronic-phase Philadelphia-chromosome- positive chronic myeloid |
leukaemia in adults |
RED Ipilimumab IV infusion 5mg/mL (NICE indications only as below) |
NICE TAG319 as an possible treatment in previously untreated advanced (unresectable or metastatic) melanoma |
NICE TA268 as a possible treatment for people with previously treated advanced (unresectable or metastatic) |
melanoma. |
RED Irinotecan concentrate for infusion 20mg/mL (NICE indication only) |
|
RED Isatuximab [Sarclisa®] (NHS England Commissioned) |
NICE TA658 Isatuximab plus pomalidomide and dexamethasone is recommended for use within the Cancer Drugs fund, as an |
option for treating relapsed and refractory multiple myeloma in adults who have had lenalidomide and a |
proteasome inhibitor, and whose disease has progressed on their last treatment, only if: |
> they have had 3 previous lines of treatment |
> the conditions in the managed access agreement for isatuximab plus pomalidomide and dexamethasone are |
followed. |
RED Ixazomib with lenalinomide and dexamethasone {Ninlaro) | NICE TA870 Recommended as an option for treating relapsed or refractory multiple myeloma in adults, only if: | > they have had 2 or 3 lines of therapy and | > the company provides ixazomib according to the commercial arrangement. | This guidance updates and replaces NICE TA505 (NHS England Commissioned) | | |
|
RED Larotrectinib |
NICE TA630 Recommended for use within the Cancer Drugs Fund as an option for treating neurotrophic tyrosine receptor kinase |
(NTRK) fusion-positive solid tumours in adults and children if: |
> the disease is locally advanced or metastatic or surgery could cause severe health problems and |
> they have no satisfactory treatment options |
It is recommended only if the conditions in the managed access agreement for larotrectinib are followed |
RED Lenvatinib is recommended as an option for untreated, advanced, unrescetable hepatocellular carcinoma in adults, |
as per NICE TA551 NHS England Commissioned |
RED Lenvatinib with everolimus for previously treated advanced renal cell carcinoma as an option as per NICE TA498 |
NHS England Commissioned |
RED Lenvatininb and sorafenib recommended as options for treating progressive, locally advanced or metastatic |
differentiated thyroid cancer (papillary, follicular or Hurthle cell) in adults whose disease does not respond to |
radioactive iodine - as per NICE TA535 NHS England Commissioned |
| RED Lenvatinib with pembrolizumab is recommended as an option for untreated advanced renal cell carcinoma in adults, only if: | > their disease is intermediate or poor risk a defined in the international Metastatic Renal cell Carcinoma Database Consortium criteria and | > nivolumab with ipilimumab would otherwiae be offered and | > the companies provide lenvatinib and pembrolizumab according to the company arrangements | See NICE TA858 NHS England Commissioned | | RED Lorlatinib tablets 25mg, 100mg {Lorviqua) (NHS England Commissioned) | NICE TA628 Recommended, within its marketing authorisation, as an option for treating anaplastic lymphoma kinase (ALK) - | positive advanced small-cell lung cancer in adults whose disease has progressed after: | > alectinib or ceritinib as the first ALK tyrosine kinase inhibitor or | > crizotinib and at least 1 other ALK tyrosine kinase inhibitor | RED Lutetium (177Lu) oxodotreotide recommended as an option for treating unresectable or metastatic, | |
progressive, well-differentiated (grade 1 or grade 2), somatostatin receptor-positive gastroenteropancreatic |
neuroendocrine tumours in adults - as per NICE TA539 (NHS England Commissioned) |
RED Midostaurin |
NICE TA523 Recommended, within its marketing authorisation, as an option in adults for treating newly diagnosed |
acute FLT3-mutation-positive myeloid leukaemia with standard daunorubicin and cytarabine as induction therapy, |
with high-dose cytarabine as consolidation therapy, and alone after complete response as maintenance therapy |
(patient access scheme) NHS England Commissioned |
NICE TA728 Midostaurin as monotherapy is recommended, within its marketing authorisation, as an option for treating |
aggressive systemic mastocytosis, systemic mastocytosis with associated haematological neoplasm, or mast cell |
leukaemia in adults. It is recommended only if the company provides midostaurin according to the |
commercial arrangement. NHS England Commissioned |
RED Mobocertinib |
NICE TA855 Mobocertinib is recommended, within its marketing authorisation, as an option for treating locally advanced or metastatic non-small-cell |
lung cancer (NSCLC) after platinum-based chemotherapy in adults whose tumours have epidermal growth factor receptor (EGFR) |
exon 20 insertion mutations. It is recommended only if the company provides it according to the commercial arrangement. |
NHS England Commissioned |
RED Neratinib tablets 40mg (Nerlynx) |
NICE TA612 Recommended as an option for the extended adjuvant treatment of hormone receptor-positive, |
human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults who completed |
adjuvant trastuzumab-based therapy less than 1 year ago only if: |
> trastuzumab is the only HER2‑directed adjuvant treatment they have had, and |
> if they had neoadjuvant chemotherapy-based regimens, they still had residual invasive disease in the breast or |
axilla following the neoadjuvant treatment, and |
> the company provides neratinib according to the commercial arrangement. (Cancer Drugs Fund) |
RED Nilotinib capsules 150mg, 200mg as an option for untreated chronic-phase Philadelphia-chromosome- positive |
chronic myeloid leukaemia in adults as per NICE TA426 Replaces NICE TA251 NHS England Commissioned |
RED Nilotinib capsules 150mg, 200mg option in treating only chronic- or accelerated- phase Philadelphia- chromosome-positive chronic myeloid leukaemia in adults as per NICE TA425 Replaces NICE TA241 | NHS England Commissioned | RED Niraparib | NICE TA528 This guidance has been updated and replaced by NICE TA784 | NICE TA673 Recommended for use within the Cancer Drugs Fund as an option for maintenance treatment for advanced | (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to | first-line platinum-based chemotherapy in adults. It is recommended only if the managed access agreement | for niraparib. (Cancer Drugs Fund) | NICE TA784 Recommended as an option for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian | tube or primary peritoneal cancer that has responded to the most recent course of patinum-based chemotherapy | in adults. It is recommended only if: | > they have BRCA mutation and have had 2 courses of platinum-based chemotherapy, or | > they do not have a BRCA mutation and have had 2 or more courses of platinum-based chemotherapy, and | > the company provides it according to the commercial arrangement. | This guidance updates and replaces NICE TA528 NHS England Commissioned | |
RED Nivolumab |
NICE TA384 intravenous infusion 10mg/ml is recommended as an option by NICE for treating advanced (unresectable or metastatic) melanoma. |
|
NICE TA400. in combination with ipilimumab is recommended, within its marketing authorisation, as an option for treating |
advanced (unresectable or metastatic) melanoma in adults, only when the company provides ipilimumab with the |
discount agreed in the patient access scheme. |
NICE TA417 recommended as an option for previously treated advanced renal cell carcinoma in adults. |
(updated September 2017 after a change to the commercial arrangements) |
NICE TA462 recommended as an option for treating relapsed or refractory classical Hodgkin lymphoma in adults after autologous |
stem cell transplant and treatment with brentuximab vedotin. (updated September 2017 after a change to the |
commercial arrangements) |
NICE TA484 recommended for use within the Cancer drugs Fund as an option for treating locally advanced or metastatic |
non-squamous non-small-cell lung cancer in adults after chemotherapy |
NICE TA490 Replaced by NICE TA736 |
NICE TA581 This guidance has been updated and replaced by NICE TA780 |
NICE TA655 Recommended as an option for treating locally advanced or metastatic squamous non-small-cell lung cancer in |
adults after chemotherapy, only if: |
> it is stopped at 2 years of uninterrupted treatment, or earlier if their disease progresses and |
> they have not had a PD-1 or PD-L1 inhibitor before. |
[Replaces NICE TA483] (NHS England Commissioned) |
NICE TA558 recommended as an option for the adjuvant treatment of completely resected melanoma in adults with lymph node |
involvement or metastatic disease. It is recommended only if the conditions in the managed access agreement are |
followed. (Cancer Drug Fund) |
NICE TA684 Recommended as an option, within its marketing authorisation, as an option for the adjuvant treatment of completely |
resected melanoma in adults with lymph node involvement or metastatic disease. It is recommended only if the |
company provides nivolumab according to the commercial arrangement. (Cancer Drug Fund) |
NICE TA707 Recommended, within its marketing authorisation, for treating unresectable advanced, recurrent or metastatic |
oesophageal squamous cell carcinoma in adults after fluoropyrimidine and platinum-based therapy. It is |
recommended only if the company provides nivolumab according to the commercial arrangement. |
(NHS England Commissioned) |
NICE TA716 Recommended as an option [plus ipilimumab], within its marketing authorisation, for treating metastatic |
colorectal cancer with high microsatellite instability [MSI] or mismatch repair [MMR] deficiency after fluoropyrimidine- |
based combination chemotherapy only if the company provides nivolumab and ipilimumab according to the |
commercial arrangement. (NHS England Commissioned) |
NICE TA736 Recommended as an option for treating recurrent or metastatic squamous cell carcinoma of the head and neck in adults whose disease has progressed on platinum-based chemotherapy, only if: | > the disease has progressed within 6 moths of having chemotherapy and | |
> the company provides it according to the commercial arrangement NHS England Commissioned |
[Replaces NICE TA490] |
NICE TA746 Recommended within its marketing authorisation, for adjuvant treatment of completely resected oesophageal |
or gastro-oesophageal junction cancer in adults who have had residual disease after previous neoadjuvant |
chemoradiotherapy. It is recommended only if the company provides nivolumab according to the |
commercial arrangement. NHS England Commissioned |
NICE TA780 Nivolumab with ipilimumab is recommended, within its marketing authorisation, as an option for untreated advanced |
renal cell carcinoma in adults: |
> whose disease is intermediate or poor risk as defined in the International Metastatic Renal Cell Carcinoma |
Database Consortium criteria and |
> only if the company provides nivolumab with ipilimumab according to the commercial arrangement. |
This guidance updates and replaces NICE TA581 NHS England Commissioned |
|
NICE TA857 Nivolumab with platinum- and fluoropyrimidine-based chemotherapy is recommneded, within its marketing authorisation, as an option for untreated HEr2-negative advanced gastric, gastro-oesophageal adenocarcinoma in adults whose tumours express PD-L1 with a combined positive score (CPS) of 5 or more. Nivolumab is only recommended if the company provides it according to the commercial arrangement. |
NHS England Commissioned NICE TA865 Nivolumab with fluoropyrimidine-based and platinum-based combination chemotherapy is recommended as an option for untreated |
unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma in adults whose tumours express PD‑L1 at a level of 1% |
or more. It is recommended only if: |
> pembrolizumab plus chemotherapy is not suitable |
> the company provides nivolumab according to the commercial arrangement. |
NHS England Commissioned |
NICE TA876 Nivolumab with chemotherapy is recommended, within its marketing authorisation, as an option for the neoadjuvant treatment of resectable |
(tumours at least 4 cm or node positive) non-small-cell lung cancer (NSCLC) in adults. It is only recommended if the company provides it according |
to the commercial arrangement. |
NHS England Commissioned |
RED Obinutuzumab [Gazyvaro] |
NICE TA513 Recommended as an option for untreated advanced follicular lymphoma(that is, first as induction treatment |
with chemotherapy, then alone as maintenance therapy), only if: |
> the person has a Follicular Lymphoma International Prognostic Index score of 2 or more |
> the company provides obinutuzumab with the discount agreed in the patient access scheme |
NHS England Commissioned) |
RED Olaparib [Lynparza] |
NICE TA381 Recommended as an option by NICE for maintenance treatment of relapsed, platinum- sensitive, BRCA mutation- |
positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based |
chemotherapy, |
NICE TA598 Recommended as an option for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian |
tube or peritoneal cancer after response to first-line platinum-based chemotherapy |
Cancer Drugs Fund |
NICE TA620 Recommended as an option for the maintenance treatment of relapsed, platinum-sensitive, high grade epithelial |
ovarian, fallopian tube or primary peritoneal cancer in adults whose disease has responded to platinum-based |
chemotherapy only if: |
> they have a BRCA1 or BRCA2 mutation |
> they have had 3 or more courses of platinum-based chemotherapy and |
> the company provides olaparib according to the commercial arrangement Cancer Drugs Fund |
|
NICE TA693 Olaparib plus bevacizumab is recommended as an option for use within the Cancer drugs fund as an option for |
maintenance treatment of advanced International Federation of Gynecology and Obstetrics [FIGO] stages 3 and 4) |
high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults when: |
> there has been a complete or partial response after first-line platinum-based chemotherapy plus bevacizumab, and |
> the cancer is associated with homologous recombination deficiency (HRD). Cancer Drugs Fund |
|
|
RED Osimertinib [Tagrisso] |
NICE TA653 Recommended as an option for treating epidermal growth factor receptor T790M mutation-positive locally advanced |
or metastatic non-small-cell lung cancer in adults only if: |
> their disease has progressed after first-line treatment with an EGFR tyrosine kinase inhibitor and |
> the company provides osimertinib according to the commercial arrangement |
[Replaces NICE TA416] (NHS England Commissioned ) |
|
NICE TA654 Recommended within its marketing authorisation, as an option for untreated locally advanced or metastatic |
epidermal growth factor receptor mutation-positive non-small-cell lung cancer in adults. |
[Replaces NICE TA621] (NHS England Commissioned ) |
|
NICE TA761 Osimertinib is recommended for use within the Cancer Drugs Fund as adjuvant treatment after complete tumour |
resection in adults with stage 1b to 3a non‑small‑cell lung cancer (NSCLC) whose tumours have epidermal growth |
factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. It is recommended only if: |
> osimertinib is stopped at 3 years, or earlier if there is disease recurrence or unacceptable toxicity and |
> the company provides osimertinib according to the managed access agreement. |
|
|
|
RED Oxaliplatin injection 50mg, 100mg (NICE indication only) RED Paclitaxel injection 30mg/5ml (NICE indication only) |
RED Paclitaxel Iv infusion - in combination with platinum as an option for treating recurrent ovarian cancer in - NICE TA389 |
RED Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer |
- an option by NICE TA476 (replaces TA360) |
RED Palbociclib |
NICE TA495 Recommended within its marketing authroisation, with an aromatase inhibitor, as an option for treating |
hormone receptor-positive , human epidermal growth receptor 2-negative, locally advanced or metastatic breast |
cancer as initial endocrine-based therapy in adults. |
NICE TA619 this NICE TA has been updated and replaced by NICE TA836 |
NICE TA836 Palbociclib plus fulvestrant is recommended as an option for treating hormone receptor‑positive, HER2‑negative |
locally advanced or metastatic breast cancer in adults who have had endocrine therapy only if: |
> exemestane plus everolimus is the most appropriate alternative to a cyclin-dependent kinase 4 and 6 (CDK4/6) |
inhibitor and |
> the company provides it according to the commercial arrangement. |
NHS England Commissioned |
RED Panitumumab is recommended, as an option for previously untreated metastatic colorectal cancer as per NICE TA 439 |
(updated Sept 2017) |
RED Panobinostat 20mg tablets - recommended as an option by NICE for treating v multiple myeloma after at least two |
previous treatments. NICE TA380 |
RED Pazopanib Tablets, f/c - recommended as a first-line treatment option for people with advanced renal cell carcinoma |
in NICE TA215 |
RED Pegaspargase as an option for treating acute lymphoblastic leukaemia in children, young people and adults only when |
they have untreated newly diagnosed disease, (as part of antineoplastic combination therapy) as recommended in NICE TA408 RED Pembrolizumab |
NICE TA428 Recommended as an option for treating locally advanced or metastatic PD-L1-positive non-small-cell lung cancer in |
adults who have had at least one chemotherapy. (NHS England Commissioned) |
NICE TA519 Recommended as an option for treating locally advanced or metastatic urothelial carcinoma after |
platinum-containing chemotherapy. |
This guidance has been updated and replaced by NICE technology appraisal guidance 692. |
NICE TA522 recommended for use within the Cancer drugs Fund as an option for untreated locally advanced or metastatic |
carcinoma in adults when cisplatin-containing chemotherapy is unsuitable |
(Guidance updated July 2018: The European medicines Agency restricted the use of pembrolizumab for untreated |
urothelial carcinoma. It should now only be used in adults with high levels of PD-L1. For more information, see the |
summary of product characteristics for pembrolizumab). (NHS England Cancer Drug Fund) |
NICE TA531 Recommended as an option for untreated PD-L1 positive metastatic non-small-cell lung cancer in adults whose |
tumours express PD-L1 (with at least 50% tumour proportion score) and have no epidermal growth factor receptor |
- or anaplastic lymphoma kinase-positive mutations. |
(replaces NICE TA447) (NHS England Commissioned) |
NICE TA540 Recommended as an option for treating relapsed or refractory classical Hodgkin lymphoma in adults who have had |
brentuximab vedotin and cannot have autologous stem cell transplant (NHS England Cancer Drug Fund) |
NICE TA553 Recommended for use within the Cancer Drug Fund as an option for the adjuvant treatment of Stage III melanoma |
with lymph node involvement in adults who have had complete resection. (NHS England Cancer Drug Fund) |
NICE TA557 Recommended for use within the Cancer Drugs Fund, with pemetrexed and platinum chemotherapy, as an option |
untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal |
growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations. |
(NHS England Cancer Drug Fund) |
NICE TA600 Recommended for use within the Cancer Drugs Fund, with carboplatin and paclitaxel, as an option for untreated |
metastatic squamous non-small-cell lung cancer in adults only if: |
> pembrolizumab is stopped at 2 years of uninterrupted treatment, or earlier if disease progresses, and |
> the company provides pembrolizumab according to the managed access agreement |
NHS England Cancer Drug Fund |
NICE TA661 Recommended as an option for untreated metastatic or unresectable recurrent head and neck squamous cell |
carcinoma in adults whose tumours express PD-L1 with a combined positive score of 1 or more. |
NHS England Commissioned |
NICE TA683 Recommended as an option with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous |
non-small-cell lung cancer in adults whose tumours have no epidermal growth factor receptor-positive or anaplastic |
lymphoma kinase-positive mutations. This is only if: |
> it is stopped at 2 years of uninterrupted treatment, or earlier if the disease progresses and |
> the company provides pembrolizumab according to the commercial arrangement (Cancer Drug Fund) |
NICE TA709 Recommended as an option for untreated metastatic colorectal cancer with high microsatellite instability (MSI) or |
mismatch repair (MMR) deficiency in adults, only if: |
> pembrolizumab is stopped after 2 years and no documented disease progression, and |
> the company provides pembrolizumab according to the commercial arrangement. |
NICE TA737 Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy is recommended, within its marketing |
authorisation, as an option for untreated locally advanced unresectable or metastatic carcinoma of the |
oesophagus or HER2‑negative gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD‑L1 |
with a combined positive score (CPS) of 10 or more. Pembrolizumab is only recommended if the company |
provides it according to the commercial arrangement. NHS England Commissioned |
NICE TA801 Pembrolizumab plus chemotherapy (paclitaxel or nab‑paclitaxel) is recommended as an option for treating |
triple‑negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy |
for metastatic disease. It is recommended only if: |
> the tumours express PD-L1 with a combined positive score (CPS) of 10 or more and an immune cell |
staining of less than 1%, and |
> the company provides pembrolizumab according to the commercial arrangement NHS England Commissioned |
NICE TA830 Pembrolizumab is recommended, within its marketing authorisation, as an option for the adjuvant treatment |
of renal cell carcinoma at increased risk of recurrence after nephrectomy, with or without metastatic lesion resection, |
with or without metastatic lesion resection, in adults. It is recommended only if the company provides it according to |
the commercial arrangement. NHS England Commissioned |
NICE TA837 Pembrolizumab is recommended, within its marketing authorisation, as an option for the adjuvant treatment of |
completely resected stage 2B or 2C melanoma in people 12 years and over. It is recommended only if the company |
provides pembrolizumab according to the commercial arrangement. NHS England Commissioned |
NICE TA851 Pembrolizumab is recommended, within its marketing authorisation, as an option with chemotherapy |
for neoadjuvant treatment and then continued alone as adjuvant treatment after surgery for adults with triple- |
negative: |
> early breast cancer at high risk of recurrence or |
> locally advanced breast cancer. |
It is recommended only if the company provides pembrolizumab according to the commercial arrangement. |
NHS England Commissioned |
NICE TA904 Pembrolizumab plus lenvatinib is recommended, within its marketing authorisation, for treating advanced or |
recurrent endometrial cancer in adults: |
> whose cancer has progressed on or after platinum-based chemotherapy and |
> who cannot have curative surgery or radiotherapy. |
Pembrolizumab plus lenvatinib is recommended only if the companies provide them according to the commercial arrangements. |
NHS England Commissioned |
RED Pemigatinib [Pemazyre® tablets 9mg/13.5mg] NHS England Commissioned |
NICE TA722 Recommended as an option, within its marketing authorisation, for treating locally advanced or metastatic |
cholangiocarcinoma with fibroblast growth factor receptor fusion or rearrangement that has progressed after |
systemic therapy in adults. It is recommended only if the company provides pemigatinib according to the |
commercial arrangement. |
RED Pentostatin injection 10mg |
RED Pertuzumab solution for infusion 30mg/mL - an option for the neoadjuvant treatment of adults with human epidermal |
growth factor receptor 2 (HER2)‑positive breast cancer, in combination with trastuzumab and chemotherapy, |
as per NICE TA424 |
RED Pertuzumab HER2-positive metastatic or locally recurrent unrescetable breast cancer in adults who have not had |
previous anti‑HER2 therapy or chemotherapy for their metastatic disease (in combination with trastuzumab and |
docetaxel - NICE TA509 |
RED Pertuzumab - NICE TA569 - Recommended, with intarvenous tarstuzumab and chemotherpay, for the adjuvant |
treatment of human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults, only if: |
> they have lymph node-positive disease |
> the company provides it according to the commercial arrangement |
NHS England Commissioned |
RED Polatuzumab vedotin [Polivy] |
NICE TA649 Polatuzumab vedotin with rituximab and bendamustine is recommended, within its marketing authorisation, as an option for treating relapsed |
or refractory diffuse large B‑cell lymphoma in adults who cannot have a haematopoietic stem cell transplant. |
It is recommended only if the company provides polatuzumab vedotin according to the commercial arrangement. NHS England Commissioned |
NICE TA874 Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin and prednisolone (R‑CHP) is recommended for untreated diffuse |
large B-cell lymphoma (DLBCL) in adults, only if |
> they have an International Prognostic Index (IPI) score of 2 to 5 |
> the company provides it according to the commercial arrangement. NHS England Commissioned |
|
RED Ponatinib - Recommended as per NICE TA451 as an option for treating chronic-accelerated -or blast - phase chronic |
myeloid leukaemia in adults. (NHS England Commissioned) |
RED Procarbazine capsules 50mg |
RED Radium-223 dichloride recommended as an option by NICE for treating hormone-relapsed pro state cancer |
with bone metastases. NICE TA376 |
|
RED Ravulizumab [Ultomiris® conc for solution for infusion] |
NICE TA698 Recommended within its marketing authorisation, as an option for treating paroxysmal nocturnal haemoglobinuria in |
adults: |
> with haemolysis with clinical symptoms suggesting high disease activity, or |
> whose disease is clinically stable after having eculizumab for at least 6 months, and |
> the company provides it according to the commercial arrangement |
NHS England Commissioned |
|
|
RED Regorafenib (Stivarga) |
NICE TA488 |
RED Regorafenib recommended as an option for treating unresectable or metastatic gastrointestinal stromal tumours |
in adults whose disease has progressed on, or who are intolerant to, prior treatment with imitinib and sunitinib |
NHS England Commissioned |
NICE TA555 |
RED Regorafenib is recommended as an option for treating advanced unrescetable hepatocellular carcinoma in adults |
who have had sorafenib, only if: |
> they have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance |
status of 0 or 1 and |
> the company provides it according to the commercial arrangement. |
NICE TA866 |
RED Regorafenib is recommended, within its marketing authorisation, as an option for metastatic colorectal cancer in adults who have had previous |
previous treatment (including fluoropyrimidine-based chemotherapy, anti‑VEGF therapy and anti‑EGFR therapy) or when these treatments are |
unsuitable. Regorafenib is only recommended if the company provides it according to the commercial arrangement. |
NHS England Commissioned |
RED Ribociclib (Kisqali) |
NICE TA496 with an aromatase inhibitor, is recommended within its marketing authorisation, as an option for treating |
hormone receptor-positive, human epidermal growth factor receptor 2‑negative, locally advanced or metastatic |
breast cancer as initial endocrine-based therapy in adults. Ribociclib is recommended only if the company provides |
it with the discount agreed in the patient access scheme. |
NICE TA593 with fulvestrant, is recommended for use within the Cancer Drug Fund as an option for treating hormone receptor- |
positive, human epidermal growth factor receptor (HER2)-negative, locally advanced or metastatic breast cancer in |
people who have had previous endocrine therapy only if: |
> exemestane plus everolimus is the most appropriate alternative to a cyclin-dependent kinase 4 and 6 |
(CDK 4/6) inhibitor and |
> the conditions in the managed access agreement for ribociclib with fulvestrant are followed. |
NICE TA687 Recommended as an option, plus fulvestrant , for treating hormone receptor-positive, human epidermal growth factor |
receptor 2 (HER-2) - negative, locally advanced or metastatic breast cancer in adults who have had previous |
endocrine therapy only if: |
> examestane plus everolimus is the most appropriate alternative to a cyclin-depnedent kinase 4 and 6 (CDK 4/6) |
inhibitor, and |
> the company provides ribociclib according to the commercial arrangement (Cancer Drug Fund) |
RED Rucaparib |
NICE TA611 Recommended for use within the Cancer Drugs Fund as an option for maintenance treatment of relapsed platinum- |
sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to |
platinum-based chemotherapy in adults, only if the conditions in the managed access agreement for rucaparib |
are followed. (Cancer Drug Fund) |
RED Ruxolitinib tablets 5mg,10mg.15mg,20mg NICE TA386 |
|
RED Selpercatinib |
NICE TA742 Recommended for use within the Cancer drugs Fund, as an option for treating: |
> advanced RET fusion-positive thyroid cancer in adults who need systemic therapy after sorafenib or lenvatinib |
> advanced RET-mutant medullary thyroid cancer in people 12 years and older who need systemic therapy after |
cabozanitinib or vandetanib |
It is recommended only if the conditions in the managed access agreement are followed. (Cancer Drug Fund) |
NICE TA760 Recommended for use within the Cancer drugs Fund, as an option for treating RET Fusion-positive advanced |
non-small-cell lung cancer in adults who need systemic therapy after immunotherapy, platinum-based |
chemotherapy or both. It is recommended only if the conditions in the managed access agreement are followed. |
Cancer Drugs Fund |
RED Sorafenib tablets 200mg recommended as an option for treating hepatocellular carcinoma only for people with |
Child-Pugh A liver impairment as per NICE TA474 |
RED Sotorasib |
NICE TA781 Sotorasib is recommended for use within the Cancer Drugs Fund as an option for treating KRAS G12C mutation- |
positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or |
cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy. It is recommended only if the |
conditions in the managed access agreement for sotorasib are followed. |
Cancer Drugs Fund |
RED Sunitinib capsules 12.5mg, 25mg, 50mg |
RED Sunitinib capsules 12.5mg, 25mg, 50mg recommended as an option treating well, or moderately differentiated |
unresectable or metastatic neuroendocrine tumours (NETs) of pancreatic origin in adults with progressive disease. |
as per NICE TA 449 NHS England Commissioned |
RED Temozolomide capsules 5mg, 20mg, 100mg,140mg, 180mg,250mg NICE TA23 (updated March 2016) |
|
RED Tepotinib |
NICE TA789 Recommended, within its marketing authorisation, as an option for treating advanced non-small-cell lung cancer with |
NETex14 skipping alterations in adults, only if the company provides tepotinib according to the commercial |
agreement. NHS England Commissioned |
RED Tisagenlecleucal is recommended for use within the cancer drug fund as an option for treating relapsed or refractory |
B-cell acute lymphoblastic leukaemia in people aged up to 25 years , as per NICE TA554 Cancer Drug Fund |
RED Tivozanib - an option in advanced renal cell carcinoma in adults as per NICE TA512 NHS England Commissioned |
RED Topotecan infusion Ovarian cancer (NICE TA91) |
RED Topotecan infusion cervical cancer, recurrent (NHS England Commissioned) |
RED Trabectedin powder for concentrate 0.25mg, 1mg (Yondelis®) |
NICE TA185 [updated February 2021] |
Recommended as a treatment option for people with advanced soft tissue sarcoma if: |
> treatment with anthracyclines and ifosfamide has failed or |
> they are intolerant of or have contraindications for treatment with anthracyclines and ifosfamide |
> Trabdectedin is only recommended if the company provides it according to the commercial arramgement |
(NHS England Commissioned) |
RED Trametininb tablets 0.5mg, 2mg as an option by NICE for treating unresectable or metastatic melanoma in |
combination with darbrafenib - NICE TA396 |
RED Trastuzumab |
NICE TA34 Trastuzumab in combination with paclitaxel (combination trastuzumab is currently only licensed for use with |
paclitaxel) is recommended as an option for people with tumours expressing human epidermal growth factor |
receptor 2 (HER2) scored at levels of 3+ who have not received chemotherapy for metastatic breast cancer and in |
whom anthracycline treatment is inappropriate. |
NICE TA208 Trastusumab [Herceptin], in combination with cisplatin and capecitabine or 5-fluorouracil, is recommended as an |
option for the treatment of people with human epidermal growth factor receptor 2 (HER2_-positive metastatic |
adenocarcinoma of the stomach or gastro-oesophageal junction who: |
° have not received prior treatment for their metastatic disease and |
° have tumours expressing hig levels of HERs as defined by a positive immunohistochemistry score of 3 (IHC3 |
positive) |
RED Trastuzumab emtansine [Kadcyla®] |
NICE TA458 Trastuzumab emtansine is recommended, within its marketing authorisation, as an option for treating a human |
epidermal growth factor receptor (HER2) - positive, unrescetable, locally advanced or metastatic breast cancer in |
adults who previously received trastuzumab and a taxane, separately or in combination - updated (replaces TA371). |
Cancer Drug Fund |
NICE TA632 Trastuzumab emtansine is recommended, within its marketing authorisation, as an option for the adjuvant |
treatment of human epidermal growth g=factor receptor 2 (HER2)- positive early breast cancer in adults who have had |
residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and HER2-targeted therapy. |
It is recommended only if the company provides trastuzumab emtansine according to the commercial arrangement |
NHS England Commissioned |
RED Trastuzumab deruxtecan [Enhertu®] |
NICE TA704 Trastuzumab deruxtecan is recommended for use within the Cancer drugs Fund as an option for treating HER2- |
positive unresectable or metastatic breast cancer in adults after 2 or more anti-HER2 therapies. It is recommended |
only if the conditions of the managed access agreement are followed. Cancer Drugs Fund |
|
NICE TA862 Trastuzumab deruxtecan is recommended with managed access as an option for treating HER2‑positive unresectable or metastatic breast cancer |
after 1 or more anti-HER2 treatments in adults. It is only recommended if the conditions in the managed access agreement for trastuzumab |
deruxtecan are followed. Cancer Drugs Fund |
RED Tretinoin capsules 10mg |
(Consultant haematologist only – use whilst waiting transfer to specialist centre - see relevant protocol) |
RED Trifluridine-tipiracil tablets 15mg, 20mg |
NICE TA405 Recommended as an option, within its marketing authorisation, as an option for treating metastatic colorectal cancer, |
that is: |
> in adults who have had previous treatment with available therapies including fluorpyrimidine-, oxaliplatin- or |
irinotecan-based chemotherapies, anti-vascular endothelial growth factor agents and anti-epidermal growth factor |
receptor agents, or when these therapies are not suitable, and |
> only when the company provides trufluridine-tipiracil with the discount agreed i the patient access scheme |
NICE TA852 Recommended, within its marketing authorisation, as an option for treating metastatic gastric cancer or gastro- |
oesophageal junction adenocarcinoma in adults who have had 2 or more treatment regimens. |
It is only recommended if the company provides trifluridine–tipiracil according to the commercial arrangement. |
This guidance updates and replaces NICE TA699 NHS England Commissioned |
RED Tucatinib tablets 50mg,100mg |
NICE TA786 Recommended with trastuzumab and capecitabine, within its marketing authorisation, as an option for treating |
HER2-positive locally advanced or metastatic breast cancer in adults after 2 or more anti-HER2 treatment therapies |
only if the company provides tucatinib according to the commercial arrangement |
NHS England Commissioned |
RED Vemfurafenib tablets 240mg |
NICE TA269 Recommended as an option for treating BRAF V600 mutation-positive unresectable or metastatic melanoma only if |
the manufacturer provides vemurafenib with the discount agreed in the patient access scheme |
RED Venetoclax [Venclyxto] |
NICE TA487 This guidance has been updated and replaced by NICE TA796 |
NICE TA561 Venetoclax with rituximab - recommended, within its marketing authorisation, as an option for treating chronic |
lymphocytic leukaemia in adults who have had at least 1 previous therapy. (Cancer Drugs Fund) |
NICE TA663 Venetoclax plus obinutuzumab is recommended as an option for untreated chronic lymphocytic leukaemia [CLL] in |
adults, only if: |
> there is a 17p deletion or TP53 mutation, or |
> there is no 17p deletion ot TP53 mutation, and fludarabine plus cyclophosphamide and rituximab [FCR], or |
bendamustine plus rituximab [BR], is unsuitable, and |
> the companies provide the drugs according to the commercial arrangements. |
Venetoclax plus obinutuzumab is recommended for use within the Cancer drugs Fund as an option for untreated CLL |
in adults, only if: |
> there is no 17p deletion or TP53 mutation, and FCR or BR is suitable, and |
> the conditions in the managed access agreement for venetoclax plus obinutuxumab are followed |
|
NICE TA765 Recommended as an option with azacitidine, within its marketing authorisation, as an option for unttreate acute |
myeloid leukaemia in adults when intensive chemotherapy is unsuitable. It is recommended only if the company |
provides venetoclax according to the commercial arrangement. NHS England Commissioned |
|
NICE TA787 Recommended as an option, with low dose cytarabine, for untreated acute myeloid leukaemia in adults when |
intensive chemotherapy is unsuitable, only if: |
> they have over 30% bone marrow blasts |
> the company provides venetoclax according to the commercial agreement |
NHS England Commissioned |
NICE TA796 Venetoclax monotherapy is recommended, within its marketing authorisation, for treating chronic lymphocytic |
leukaemia in adults: |
> with a 17p deletion or TP53 mutation and when a B-cell receptor pathway inhibitor is unsuitable, or whose |
disease has progressed after a B=cell receptor pathway inhibitor ir |
> without a 17p deletion or TP53 mutation, and whose disease has progressed after both chemo-immunotherapy |
and a B-cell receptor pathway inhibitor |
It is recommended only if the company provides venetoclax according to the commercial arrangement |
This guidance updates and replaces NICE TA487 NHS England Commissioned |
|
RED Zanubrutinib (Brukinsa) NHS England Commissioned |
NICE TA833 recommended as an option for treating Waldenstrom's macroglobulinaemia in adults who have had at least 1 treatment, only if: |
> bendamustine plus rituximab is also suitable and |
> the company provides it according to the commercial arrangement. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|